Keith W. Pratz

14.2k total citations · 5 hit papers
128 papers, 5.2k citations indexed

About

Keith W. Pratz is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Keith W. Pratz has authored 128 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Hematology, 46 papers in Molecular Biology and 37 papers in Genetics. Recurrent topics in Keith W. Pratz's work include Acute Myeloid Leukemia Research (109 papers), Chronic Myeloid Leukemia Treatments (48 papers) and Acute Lymphoblastic Leukemia research (27 papers). Keith W. Pratz is often cited by papers focused on Acute Myeloid Leukemia Research (109 papers), Chronic Myeloid Leukemia Treatments (48 papers) and Acute Lymphoblastic Leukemia research (27 papers). Keith W. Pratz collaborates with scholars based in United States, Australia and France. Keith W. Pratz's co-authors include Mark J. Levis, Courtney D. DiNardo, Jalaja Potluri, Brenda Chyla, Brian A. Jonas, Marina Konopleva, Daniel A. Pollyea, Andrew H. Wei, Hagop M. Kantarjian and Anthony Letai and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Keith W. Pratz

126 papers receiving 5.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. profile →
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

2009 474 citations Keith W. Pratz, Mark J. Levis et al. Blood profile →
Recent advances in targeted therapies in acute myeloid leukemia

2023 137 citations Keith W. Pratz et al. profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Peers

Countries citing papers authored by Keith W. Pratz

Since Specialization

Citations

This map shows the geographic impact of Keith W. Pratz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith W. Pratz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith W. Pratz more than expected).

Fields of papers citing papers by Keith W. Pratz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith W. Pratz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith W. Pratz. The network helps show where Keith W. Pratz may publish in the future.

Co-authorship network of co-authors of Keith W. Pratz

This figure shows the co-authorship network connecting the top 25 collaborators of Keith W. Pratz. A scholar is included among the top collaborators of Keith W. Pratz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith W. Pratz. Keith W. Pratz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ven the dose matters: Venetoclax dosing in the frontline treatment of AML 2024 ·Blood Reviews ·Dahniel Sastow, (unknown), (unknown), Keith W. Pratz, Douglas Tremblay	2
2	Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML 2023 ·Journal of Clinical Oncology ·Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, Nikolai A. Podoltsev, José C. Cruz, Tara L. Lin, Gary J. Schiller, Joseph G. Jurcic, Adam Asch, (unknown), Jason E. Hill, Stanley C. Gill, (unknown), Elizabeth Rich, Nahla Hasabou, Alexander E. Perl, Mark J. Levis	27
3	Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis 2023 ·Value in Health ·Xue Li, Hae Sun Suh, Jean Lachaîne, Andre C. Schuh, Keith W. Pratz, Keith A. Betts, Jinlin Song, (unknown), Cat N. Bui	2
4	Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia 2022 ·Blood Advances ·Andrew Matthews, Alexander E. Perl, Selina M. Luger, Alison W. Loren, Saar Gill, David L. Porter, Daria V. Babushok, Ivan Maillard, Martin Carroll, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Vikram R. Paralkar, (unknown), Wei‐Ting Hwang, David M. Margolis, Keith W. Pratz	53
5	Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies 2022 ·Transplantation and Cellular Therapy ·(unknown), Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, (unknown), (unknown), Jacqueline Smith, (unknown), Alexis Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey	2
6	Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia 2022 ·Clinical Cancer Research ·Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei	59
7	Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine 2022 ·Clinical Cancer Research ·Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo	75
8	POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy 2022 ·Value in Health ·Keith W. Pratz, Jean Lachaîne, (unknown), (unknown), (unknown), (unknown), Jipan Xie, (unknown), (unknown)	2
9	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia 2021 ·Leukemia Research ·Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, (unknown), B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy E. DeZern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel, Judith E. Karp	10
10	BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies 2019 ·Clinical Cancer Research ·Weijie Poh, Robert L. Dilley, Alison R. Moliterno, Jaroslaw P. Maciejewski, Keith W. Pratz, Michael A. McDevitt, James G. Herman	10
11	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study 2019 ·Blood ·James M. Foran, Zhuoxin Sun, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, Jacob M. Rowe, Elisabeth Paietta, Janis Racevskis, Jessica K. Altman, Selina M. Luger, Aref Al‐Kali, Hong Zheng, Keith W. Pratz, E. Randolph Broun, Bayard L. Powell, Kristen M. O’Dwyer, John E. Godwin, Yishai Ofran, Mark R. Litzow, Martin S. Tallman	24
12	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years 2018 ·Blood ·James M. Foran, Zhuoxin Sun, Elisabeth Paietta, Janis Racevskis, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, Jacob M. Rowe, John E. Godwin, Yanming Zhang, Martin S. Tallman, Mark R. Litzow, Keith W. Pratz, Selina M. Luger	4
13	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies 2017 ·Cancer Research ·(unknown), S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small	32
14	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies 2017 ·Clinical Cancer Research ·(unknown), Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, Michelle A. Rudek	4
15	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia 2016 ·Clinical Cancer Research ·Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary L. Rosner, Alice P. Chen, Scott H. Kaufmann, Judith E. Karp	38
16	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms 2016 ·Clinical Cancer Research ·Keith W. Pratz, Brian D. Koh, Anand G. Patel, Karen S. Flatten, Weijie Poh, James G. Herman, Robert L. Dilley, Maria I. Harrell, B. Douglas Smith, Judith E. Karp, Elizabeth M. Swisher, Michael A. McDevitt, Scott H. Kaufmann	23
17	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia 2012 ·Haematologica ·(unknown), Elizabeth Garrett‐Mayer, Elihu H. Estey, Michelle A. Rudek, Benjamin D. Smith, Judith M. Greer, (unknown), Katherine Mackey, Kathleen Shannon Dorcy, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle, James R. Wright, John M. Pagel	49
18	Intestinal Lymphangiectasia With Protein-Losing Enteropathy in Waldenstrom Macroglobulinemia 2007 ·Medicine ·Keith W. Pratz, David Dingli, Thomas C. Smyrk, John A. Lust	17
19	Large Cell Carcinoma With Calcitonin and Vasoactive Intestinal Polypeptide–Associated Verner-Morrison Syndrome 2005 ·Mayo Clinic Proceedings ·Keith W. Pratz, X. Cynthia, Marie‐Christine Aubry, Terri J. Vrtiska, Charles Erlichman	6
20	Large Cell Carcinoma With Calcitonin and Vasoactive Intestinal Polypeptide–Associated Verner-Morrison Syndrome 2005 ·Mayo Clinic Proceedings ·Keith W. Pratz, X. Cynthia, Marie-Christine Aubry, Terri J. Vrtiska, Charles Erlichman	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact